Literature DB >> 4015949

Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.

J L Boublil, G Milano, R Khater, J Bourry, A Thyss, J N Bruneton, N Renée, C Philip, M Namer.   

Abstract

Eighteen patients with liver metastasis or locoregional recurrence of colon carcinoma received locoregional treatment by continuous 5-day infusions of 5-FU. 5-FU blood levels were measured by HPLC every day of the cycle at 8 am and 5 pm for a total of 87 cycles. Twelve patients were given the drug by an intra-arterial hepatic (i.a.h.) route, 3 by the portal vein (i.p.v.) and 3 by an intra-arterial pelvic (i.a.p.) route. These three routes were compared in respect of their relative pre-systemic drug uptake and the effect of dose escalation. Both the i.a.h. and i.p.v. routes, but not the i.a.p. route, resulted in a significant reduction in AUC 0-105 h compared to the i.v. route at the same dose range. Increasing the dose led to a modification in circulating 5-FU levels proportional to the dose for the i.v. and i.a.p. routes. By contrast, for the i.a.h. and i.p.v. routes, systemic drug delivery was significantly elevated, out of proportion with the dose, indicating a saturable process. For the i.a.h. route, increasing the 5-FU dose from 780 to 1000 mg m-2 day-1 caused a drop in hepatic extraction from 0.93 (0.90-0.95) to 0.44 (0.21-0.66). Liver saturation mechanisms were also evidenced by a mean increase of 2.6 times for the circulating drug level during the second part of the cycle as compared to the first part (P less than 0.001). The evolution of 5-FU AUC 0-105 h as a function of the dose was exponential (r = 0.75, P less than 0.001). Local extraction consecutive to i.a.p. was non-existent, implying that this route of drug administration has no potential advantage over classical i.v. infusion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015949      PMCID: PMC1977180          DOI: 10.1038/bjc.1985.142

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Treatment of hepatic metastases by percutaneous hepatic arterial infusion.

Authors:  J A Petrek; J P Minton
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

2.  Intrahepatic arterial infusion with 5-fluorouracil.

Authors:  F J Ansfield; G Ramirez; J L Skibba; G T Bryan; H L Davis; G W Wirtanen
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

3.  The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to "small" and "large" tumors.

Authors:  N B Ackerman; W M Lien; E S Kondi; N A Silverman
Journal:  Surgery       Date:  1969-12       Impact factor: 3.982

4.  Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses.

Authors:  H S Chen; J F Gross
Journal:  Cancer Treat Rep       Date:  1980-01

5.  Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma.

Authors:  N Christophidis; G Mihaly; F Vajda; W Louis
Journal:  Clin Chem       Date:  1979-01       Impact factor: 8.327

6.  Chemotherapy of large bowel cancer.

Authors:  H L Davis
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

Review 7.  Dose-dependent pharmacokinetics and cancer chemotherapy.

Authors:  G Powis; M M Ames; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  The design and initial testing of an implantable infusion pump.

Authors:  P J Blackshear; F D Dorman; P L Blackshear; R L Varco; H Buchwald
Journal:  Surg Gynecol Obstet       Date:  1972-01

9.  Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugs.

Authors:  K F Aronsen; C Hellekant; J Holmberg; U Rothman; H Teder
Journal:  Eur Surg Res       Date:  1979       Impact factor: 1.745

10.  Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.

Authors:  J L Speyer; P H Sugarbaker; J M Collins; R L Dedrick; R W Klecker; C E Myers
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

View more
  9 in total

1.  No evidence of gemcitabine accumulation during weekly administration.

Authors:  S M de Lange; K van der Born; J R Kroep; H A Jensen; P Pfeiffer; A Cleverly; C J van Groeningen; G J Peters
Journal:  Eur J Clin Pharmacol       Date:  2005-11-10       Impact factor: 2.953

2.  The re-birth of hepatic arterial infusion for colorectal liver metastases.

Authors:  Nancy E Kemeny
Journal:  J Gastrointest Oncol       Date:  2013-06

3.  Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.

Authors:  Yang Hyun Baek; Kyoung Tae Kim; Sung Wook Lee; Jin Sook Jeong; Byeong Ho Park; Kyung Jin Nam; Jin Han Cho; Young Hoon Kim; Young Hoon Roh; Hyung Sik Lee; Young Min Choi; Sang Young Han
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

4.  Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy.

Authors:  G Milano; M Namer; J L Boublil; R Khater; M Frenay; A Thyss; J Bourry; C Philip; N Renée; J N Bruneton
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Combined haemoperfusion, haemofiltration and haemodialysis for systemic detoxification in locoregional 5-fluorouracil therapy.

Authors:  F Keller; U Gallkowski; W Roth; J Boese-Landgraf
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.

Authors:  L Thiberville; P Compagnon; N Moore; G Bastian; M O Richard; M F Hellot; C Vincent; M M Kannass; S Dominique; C Thuillez
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.

Authors:  S Fujii; M Fukushima; Y Shimamoto; T Shirasaka
Journal:  Jpn J Cancer Res       Date:  1989-06

8.  Development of in situ gelling and bio adhesive 5-Fluorouracil enema.

Authors:  Lu-Lu Wang; Wen-Sheng Zheng; Shao-Hua Chen; Xia-Qin Fang
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

9.  Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats.

Authors:  S Fujii; Y Shimamoto; H Ohshimo; T Imaoka; M Motoyama; M Fukushima; T Shirasaka
Journal:  Jpn J Cancer Res       Date:  1989-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.